EU's Innovative Medicines Initiative joins hands with US Critical Path Institute
This article was originally published in SRA
The EU Innovative Medicines Initiative has signed a memorandum of understanding with the Critical Path Institute (C-Path) in the US to further the shared objective the two public-private organisations have of accelerating the development of safer, more effective medicines1.
You may also be interested in...
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.